A Phase 1, SAD and MAD Study to Evaluate the Safety and Tolerability of FB418
A Phase 1, SAD and MAD Study to Evaluate the Safety and Tolerability of FB418
Recruiting · NCT05995782 · Registry updated 2024-12-02Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase 1, SAD and MAD Study to Evaluate the Safety and Tolerability of FB418 | Nutritional and Metabolic Diseases, TDP-43 proteinopathy, amyotrophic lateral sclerosis, central nervous system disorder, metabolic disease, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, spinal cord disorder | Recruiting | Phase 1 | 2024-12-02 | NCT05995782 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| 1ST Biotherapeutics, Inc. | 3 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Seoul National University | Seoul | South Korea | 4 |